- Home
- ATHA vs MDRR Comparison
ATHA vs MDRR Comparison
Compare ATHA & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- MDRR
- Stock Information
- Founded
- ATHA 2011
- MDRR 2015
- Country
- ATHA United States
- MDRR United States
- Employees
- ATHA N/A
- MDRR N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- MDRR Real Estate Investment Trusts
- Sector
- ATHA Health Care
- MDRR Real Estate
- Exchange
- ATHA Nasdaq
- MDRR Nasdaq
- Market Cap
- ATHA 16.1M
- MDRR 18.0M
- IPO Year
- ATHA 2020
- MDRR 2018
- Fundamental
- Price
- ATHA $4.11
- MDRR $13.00
- Analyst Decision
- ATHA
- MDRR
- Analyst Count
- ATHA 0
- MDRR 0
- Target Price
- ATHA N/A
- MDRR N/A
- AVG Volume (30 Days)
- ATHA 27.3K
- MDRR 663.0
- Earning Date
- ATHA 11-06-2025
- MDRR 11-11-2025
- Dividend Yield
- ATHA N/A
- MDRR 2.08%
- EPS Growth
- ATHA N/A
- MDRR N/A
- EPS
- ATHA N/A
- MDRR N/A
- Revenue
- ATHA N/A
- MDRR $9,649,145.00
- Revenue This Year
- ATHA N/A
- MDRR N/A
- Revenue Next Year
- ATHA N/A
- MDRR N/A
- P/E Ratio
- ATHA N/A
- MDRR N/A
- Revenue Growth
- ATHA N/A
- MDRR N/A
- 52 Week Low
- ATHA $2.20
- MDRR $9.55
- 52 Week High
- ATHA $8.26
- MDRR $15.00
- Technical
- Relative Strength Index (RSI)
- ATHA 59.40
- MDRR 47.68
- Support Level
- ATHA $3.95
- MDRR $13.01
- Resistance Level
- ATHA $4.50
- MDRR $13.45
- Average True Range (ATR)
- ATHA 0.24
- MDRR 0.13
- MACD
- ATHA -0.05
- MDRR -0.11
- Stochastic Oscillator
- ATHA 55.81
- MDRR 28.57
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.